Boston Scientific (BSX) is back in focus after reporting strong pivotal trial data for its SEISMIQ 4CE coronary intravascular lithotripsy catheter, which met key safety and effectiveness goals in patients with severely calcified coronary artery disease.

The strong SEISMIQ 4CE trial update comes against a weak recent trading backdrop, with the share price down 16% over 30 days and the 1-year total shareholder return down 53%, although the 5-year total shareholder return remains positive.

If this kind of medical technology story interests you, it can be worth widening your search to other healthcare-focused opportunities using our 35 healthcare AI stocks

With the stock down sharply over the past year but trading at a sizeable discount to recent analyst targets and intrinsic value estimates, should you see Boston Scientific as mispriced today, or has the market already factored in its future growth?

Most Popular Narrative: 50.3% Undervalued

Boston Scientific's most followed narrative pegs fair value at $98.90 per share, roughly double the last close at $49.11, which naturally raises questions about what is driving such a large gap.

The immediate impact of the Penumbra acquisition has been somewhat heavy on the stock’s valuation for a few key reasons:

• Earnings Dilution: The acquisition is expected to be dilutive to adjusted earnings per share (EPS) by approximately $0.06 to $0.08 in the first full year. Investors often react to this "EPS drag" by pulling back, which has been reflected in the recent price dips.
• Increased Debt Load: BSX is financing a significant portion of this deal (about $11 billion) with new debt. This has raised concerns about the company''s leverage, with projections reaching 3.3x adjusted EBITDA leverage by the end of 2026.
• Valuation Premium: Some market participants feel the $14.5 billion price tag was high, leading to a "show me" period where the stock price remains under pressure until the integration proves successful.

The narrative, according to Bill_S, focuses on faster growth from neurovascular and thrombectomy markets, rising earnings power after integration, and a richer profit profile that supports that higher fair value without relying on short term trading signals.

Result: Fair Value of $98.90 (UNDERVALUED)

However, this hinges on smooth integration and execution, and any setback in Penumbra related synergies or concerns around the larger debt load could quickly challenge that upside story.

Next Steps

If the mixed sentiment so far leaves you on the fence, it can be beneficial to study the details yourself and act promptly while others hesitate, starting with the 5 key rewards

Looking for more investment ideas?

If this update has sharpened your interest, do not stop at one stock. Broaden your watchlist now using focused screeners built to surface clear, data backed opportunities.

• Spot potential value opportunities early by scanning 46 high quality undervalued stocks before others catch on.
• Secure potential income ideas by reviewing 10 dividend fortresses that may suit a yield focused approach.
• Sleep a little easier by checking 64 resilient stocks with low risk scores that score well on resilience metrics.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.